

Anacor Pharmaceuticals Inc  
Form SC 13D/A  
March 01, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D/A  
Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

ANACOR PHARMACEUTICALS, INC.  
(Name of Issuer)

Common Stock, \$0.001 Par Value  
(Title of Class of Securities)

032420 101  
(CUSIP Number)

Victoria A. Whyte  
GlaxoSmithKline plc  
980 Great West Road  
Brentford, Middlesex TW8 9GS  
Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 14, 2012  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.



CUSIP No. 032420 101

SCHEDULE 13D/A

Page 2 of 7

- 1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
GlaxoSmithKline plc
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a)   
(b)
- 3 SEC USE ONLY
- 4 SOURCE OF FUNDS  
WC
- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
- 6 CITIZENSHIP OR PLACE OF ORGANIZATION  
England and Wales
- |   |    |                          |  |
|---|----|--------------------------|--|
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7  | SOLE VOTING POWER        |  |
|   |    | 2,771,374                |  |
|   | 8  | SHARED VOTING POWER      |  |
|   |    | -0-                      |  |
|   | 9  | SOLE DISPOSITIVE POWER   |  |
|   |    | 2,771,374                |  |
|   | 10 | SHARED DISPOSITIVE POWER |  |
|   |    | -0-                      |  |
- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,771,374 shares of Common Stock (1)
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
7.8% of the shares of Common Stock (2)
- 14 TYPE OF REPORTING PERSON  
CO

## Footnotes:

- (1) Shares held of record by GlaxoSmithKline LLC f/k/a SmithKline Beecham Corporation, a wholly owned subsidiary of the Reporting Person, issued as of November 30, 2010.
- (2) Based on 35,568,645 shares of Common Stock as of November 30, 2012.

CUSIP No. 032420 101

SCHEDULE 13D/A

Page 3 of 7

This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (the “Original Schedule 13D”) with respect to the shares of common stock, par value \$0.001 per share (the “Common Stock”), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.

Item 2. Identity and Background.

The response set forth in Item 2 of the Original Schedule 13D is hereby amended by deleting Schedule 1 in its entirety, and replacing it with Schedule 1 attached hereto.

Item 5. Interest in Securities of the Issuer.

The response set forth in the first paragraph of Item 5 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

(a) GlaxoSmithKline plc beneficially owns 2,771,374 shares of Common Stock, issued as of November 30, 2010, which represents 7.8% of the 35,568,645 shares of Common Stock outstanding as of November 30, 2012. The Issuer issued an additional 3,250,000 shares of Common Stock on February 14, 2012 and 4,000,000 shares of Common Stock on October 23, 2012.

---

CUSIP No. 032420 101

SCHEDULE 13D/A

Page 4 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

GLAXOSMITHKLINE PLC

/s/ Victoria A. Whyte

By: Victoria A. Whyte

Title: Company Secretary

---

CUSIP No. 032420 101

SCHEDULE 13D/A

Page 5 of 7

## SCHEDULE I

Name	Business Address	Principal Occupation or Employment	Citizenship
Board of Directors			
Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Chief Executive Officer	British
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS	Chief Financial Officer	British
Dr. Moncef Slaoui	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director Chairman Global Research & Development and Vaccines	Moroccan, Belgian & US
Sir Christopher Gent	980 Great West Road Brentford Middlesex, England TW8 9GS	Chairman and Company Director	British
Professor Sir Roy Anderson	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Dr. Stephanie Burns	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Stacey Cartwright	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Sir Crispin Davis	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British

Edgar Filing: Anacor Pharmaceuticals Inc - Form SC 13D/A

Judy Lewent	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Sir Deryck Maughan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British

---

CUSIP No. 032420 101

SCHEDULE 13D/A

Page 6 of 7

Name	Business Address	Principal Occupation or Employment	Citizenship
Dr. Daniel Podolsky	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Tom de Swaan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	Dutch
Sir Robert Wilson	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Lynn Elsenhans	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Jing Ulrich	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Hans Wijers*	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	Dutch

\*Appointment with effect from 1 April 2013

Corporate  
Executive Team

Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Chief Executive Officer	British
Simon Dingemans	980 Great West Road		British



Edgar Filing: Anacor Pharmaceuticals Inc - Form SC 13D/A

	Brentford Middlesex, England TW8 9GS	Executive Director and Chief Financial Officer	
Dr. Moncef Slaoui	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director Chairman Global Research & Development and Vaccines	Moroccan, Belgian & US
Simon Bicknell	980 Great West Road Brentford Middlesex, England TW8 9GS	Senior Vice President, Governance, Ethics and Assurance	British
Deirdre Connelly	1600 Vine Street, Philadelphia, PA 19102	President, North America Pharmaceuticals	US

---

CUSIP No. 032420 101

SCHEDULE 13D/A

Page 7 of 7

Name	Business Address	Principal Occupation or Employment	Citizenship
Marc Dunoyer	980 Great West Road Brentford Middlesex, England TW8 9GS	Head of Rare Diseases Unit and Chairman of GlaxoSmithKline Japan	French
Abbas Hussain	150 Beach Road 22-00 Gateway West 189720 Singapore	President, Europe & Emerging Markets & Asia Pacific	British
William Louv	Five Moore Drive PO Box 13398 Research Triangle Park North Carolina 27709	Senior Vice President, Core Business Services & Chief Information Officer	US